ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet2017319-24ometendo-9446Research ArticleОбзор литературыReviewВлияние андрогенного дефицита на состояние углеводного обмена у мужчинInfluence of androgen deficiency on carbohydrate metabolism in menМкртумянАшот МусаеловичMkrtumyanAshot M.

д.м.н., профессор

Sc.D., professor

vagrashot@mail.ruЕгшатянЛилит ВаниковнаEgshatyanLilit V.

к.м.н.

к.м.н.

lilit.egshatyan@yandex.ru<p class="address">ФГБОУ ВО МГМСУ им. А.И. Евдокимова Минздрава России;&nbsp; ГБУЗ города Москвы Московский Клинический Научно-практический Центр имени А.С. Логинова Департамента здравоохранения города Москвы</p>Россия<p class="Rezume">A.I. Evdokimov Moscow State University of Medicine and Dentistry; The Loginov Moscow Clinical Scientific Center</p>Russian Federation<p class="address">ГБУЗ города Москвы Московский Клинический Научно-практический Центр имени А.С. Логинова Департамента здравоохранения города Москвы; ФГБУ &laquo;Национальный медицинский исследовательский центр эндокринологии&raquo; Минздрава России</p>Россия<p class="Rezume">The Loginov Moscow Clinical Scientific Center; Endocrinology Research Centre</p>Russian Federation2017131120171431924Copyright &#x00A9; Мкртумян А.М., Егшатян Л.В., 20172017Мкртумян А.М., Егшатян Л.В.Mkrtumyan A.M., Egshatyan L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/9446

В статье представлен обзор современной литературы, обобщающий клинические данные о роли андрогенодефицита в патогенезе метаболических нарушений и сахарного диабета 2 типа у мужчин. Сочетание андрогенодефицита и сахарного диабета 2 типа является сильным фактором риска сердечно-сосудистых заболеваний. В связи с незнанием проблемы андрогенодефицита врачами общей практики, эндокринологами, большинство случаев остается не только без лечения, но и не выявляется.

The article provides an overview of the current literature integrating clinical data on the role of androgen deficiency in pathogenesis of metabolic malfunctions and diabetes mellitus. The combination of androgen deficiency and diabetes mellitus is a risk factor of cardiovascular diseases. Due to the fact that general physicians, endocrinologist don’t have knowledge of this problem most of androgen deficiency cases are not only remained without treatment but also not revealed.

тестостеронандрогенный дефицитожирениесахарный диабетинсулинорезистентностьtestosteroneandrogen deficiencyobesitymetabolic malfunctionsdiabetes mellitusinsulinresistanceReferencesStellato RK, Feldman HA, Hamdy O, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care. 2000;23(4):490-494. doi: 10.2337/diacare.23.4.490.Stellato RK, Feldman HA, Hamdy O, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care. 2000;23(4):490-494. doi: 10.2337/diacare.23.4.490.Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone Deficiency. The American Journal of Medicine. 2011;124(7):578-587. doi: 10.1016/j.amjmed.2010.12.027.Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone Deficiency. The American Journal of Medicine. 2011;124(7):578-587. doi: 10.1016/j.amjmed.2010.12.027.Тюзиков И.А. Результаты пилотного эпидемиологического исследования распространенности андрогенного дефицита у мужчин в амбулаторной практике врачей различных специальностей (Ярославское исследование) //Андрология и генитальная хирургия. – 2013. – №. 3. – С. 23-28. [Tyuzikov IA. Results of pilot epidemiological study of androgen deficiency prevalence at men in ambulance practice of various specialities’ doctors (Yaroslavl study). Andrologiya i genital'naya khirurgiya. 2013;(3):23-28 (In Russ)]Тюзиков И.А. Результаты пилотного эпидемиологического исследования распространенности андрогенного дефицита у мужчин в амбулаторной практике врачей различных специальностей (Ярославское исследование) //Андрология и генитальная хирургия. – 2013. – №. 3. – С. 23-28. [Tyuzikov IA. Results of pilot epidemiological study of androgen deficiency prevalence at men in ambulance practice of various specialities’ doctors (Yaroslavl study). Andrologiya i genital'naya khirurgiya. 2013;(3):23-28 (In Russ)]Kupelian V, Shabsigh R, Araujo AB, et al. Erectile Dysfunction as a Predictor of the Metabolic Syndrome in Aging Men: Results From the Massachusetts Male Aging Study. The Journal of Urology. 2006;176(1):222-226. doi: 10.1016/s0022-5347(06)00503-9.Kupelian V, Shabsigh R, Araujo AB, et al. Erectile Dysfunction as a Predictor of the Metabolic Syndrome in Aging Men: Results From the Massachusetts Male Aging Study. The Journal of Urology. 2006;176(1):222-226. doi: 10.1016/s0022-5347(06)00503-9.Allan CA, Strauss BJG, McLachlan RI. Body composition, metabolic syndrome and testosterone in ageing men. Int J Impot Res. 2007;19(5):448-457. doi: 10.1038/sj.ijir.3901552.Allan CA, Strauss BJG, McLachlan RI. Body composition, metabolic syndrome and testosterone in ageing men. Int J Impot Res. 2007;19(5):448-457. doi: 10.1038/sj.ijir.3901552.Goulis DG, Tarlatzis BC. Metabolic syndrome and reproduction: I. Testicular function. Gynecol Endocrinol. 2009;24(1):33-39. doi: 10.1080/09513590701582273.Goulis DG, Tarlatzis BC. Metabolic syndrome and reproduction: I. Testicular function. Gynecol Endocrinol. 2009;24(1):33-39. doi: 10.1080/09513590701582273.Kershaw EE, Flier JS. Adipose Tissue as an Endocrine Organ. J Clin Endocr Metab. 2004;89(6):2548-2556. doi: 10.1210/jc.2004-0395.Kershaw EE, Flier JS. Adipose Tissue as an Endocrine Organ. J Clin Endocr Metab. 2004;89(6):2548-2556. doi: 10.1210/jc.2004-0395.Mah PM, Wittert GA. Obesity and testicular function. Mol Cell Endocrinol. 2010;316(2):180-186. doi: 10.1016/j.mce.2009.06.007.Mah PM, Wittert GA. Obesity and testicular function. Mol Cell Endocrinol. 2010;316(2):180-186. doi: 10.1016/j.mce.2009.06.007.Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocr Metab. 2006;91(6):1995-2010. doi: 10.1210/jc.2005-2847.Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocr Metab. 2006;91(6):1995-2010. doi: 10.1210/jc.2005-2847.Defay R, Papoz L, Barny S, et al. Hormonal status and NIDDM in the European and Melanesian populations of New Caledonia: a case-control study. Int J Obes. 1998;22(9):927-934. doi: 10.1038/sj.ijo.0800697.Defay R, Papoz L, Barny S, et al. Hormonal status and NIDDM in the European and Melanesian populations of New Caledonia: a case-control study. Int J Obes. 1998;22(9):927-934. doi: 10.1038/sj.ijo.0800697.Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl. 2009;32(6):587-598. doi: 10.1111/j.1365-2605.2008.00951.x.Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl. 2009;32(6):587-598. doi: 10.1111/j.1365-2605.2008.00951.x.Simon D. Association between Plasma Total Testosterone and Cardiovascular Risk Factors in Healthy Adult Men: The Telecom Study. J Clin Endocrinol Metab. 1997;82(2):682-685. doi: 10.1210/jc.82.2.682.Simon D. Association between Plasma Total Testosterone and Cardiovascular Risk Factors in Healthy Adult Men: The Telecom Study. J Clin Endocrinol Metab. 1997;82(2):682-685. doi: 10.1210/jc.82.2.682.De Maddalena C, Vodo S, Petroni A, Aloisi AM. Impact of testosterone on body fat composition. J Cell Physiol. 2012;227(12):3744-3748. doi: 10.1002/jcp.24096.De Maddalena C, Vodo S, Petroni A, Aloisi AM. Impact of testosterone on body fat composition. J Cell Physiol. 2012;227(12):3744-3748. doi: 10.1002/jcp.24096.Chen RYT, Wittert GA, Andrews GR. Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes, Obesity and Metabolism. 2006;8(4):429-435. doi: 10.1111/j.1463-1326.2005.00532.x.Chen RYT, Wittert GA, Andrews GR. Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes, Obesity and Metabolism. 2006;8(4):429-435. doi: 10.1111/j.1463-1326.2005.00532.x.Camacho EM, Huhtaniemi IT, O'Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. European Journal of Endocrinology. 2013;168(3):445-455. doi: 10.1530/eje-12-0890.Camacho EM, Huhtaniemi IT, O'Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. European Journal of Endocrinology. 2013;168(3):445-455. doi: 10.1530/eje-12-0890.Muller M, Grobbee DE, den Tonkelaar I, et al. Endogenous Sex Hormones and Metabolic Syndrome in Aging Men. J Clin Endocr Metab. 2005;90(5):2618-2623. doi: 10.1210/jc.2004-1158.Muller M, Grobbee DE, den Tonkelaar I, et al. Endogenous Sex Hormones and Metabolic Syndrome in Aging Men. J Clin Endocr Metab. 2005;90(5):2618-2623. doi: 10.1210/jc.2004-1158.Björntorp P. Fatty acids, hyperinsulinemia, and insulin resistance: which comes first? Curr Opin Lipidol. 1994;5(3):166-174. doi: 10.1097/00041433-199405030-00003.Björntorp P. Fatty acids, hyperinsulinemia, and insulin resistance: which comes first? Curr Opin Lipidol. 1994;5(3):166-174. doi: 10.1097/00041433-199405030-00003.Schroeder ET, Zheng L, Ong MD, et al. Effects of Androgen Therapy on Adipose Tissue and Metabolism in Older Men. J Clin Endocr Metab. 2004;89(10):4863-4872. doi: 10.1210/jc.2004-0784.Schroeder ET, Zheng L, Ong MD, et al. Effects of Androgen Therapy on Adipose Tissue and Metabolism in Older Men. J Clin Endocr Metab. 2004;89(10):4863-4872. doi: 10.1210/jc.2004-0784.Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. The Aging Male. 2009;6(1):1-7. doi: 10.1080/tam.6.1.1.7.Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. The Aging Male. 2009;6(1):1-7. doi: 10.1080/tam.6.1.1.7.Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. The Aging Male. 2015;18(1):5-15. doi: 10.3109/13685538.2015.1004049.Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. The Aging Male. 2015;18(1):5-15. doi: 10.3109/13685538.2015.1004049.Dohle, Jones T.H., Kliesch S, Punab M. Guidelines on Male Hypogonadism, EAU 2015.Dohle, Jones T.H., Kliesch S, Punab M. Guidelines on Male Hypogonadism, EAU 2015.Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocr Metab. 2010;95(6):2536-2559. doi: 10.1210/jc.2009-2354.Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocr Metab. 2010;95(6):2536-2559. doi: 10.1210/jc.2009-2354.Layton JB, Meier CR, Sharpless JL, et al. Comparative Safety of Testosterone Dosage Forms. JAMA Internal Medicine. 2015;175(7):1187. doi: 10.1001/jamainternmed.2015.1573.Layton JB, Meier CR, Sharpless JL, et al. Comparative Safety of Testosterone Dosage Forms. JAMA Internal Medicine. 2015;175(7):1187. doi: 10.1001/jamainternmed.2015.1573.Аметов А.С., Пашкова Е.Ю. Эволюция тестостеронзаместительной терапии. Новые формы – новые возможности. Эндокринология: новости, мнения, обучение. – 2017. – № 2. – С. 55-65. [Ametov AS, Pashkova EY. Evolyutsiya testosteronzamestitel'noy terapii. Novye formy – novye vozmozhnosti. Endokrinologiya: novosti, mneniya, obuchenie. 2017;(2):55-65. (In Russ)]Аметов А.С., Пашкова Е.Ю. Эволюция тестостеронзаместительной терапии. Новые формы – новые возможности. Эндокринология: новости, мнения, обучение. – 2017. – № 2. – С. 55-65. [Ametov AS, Pashkova EY. Evolyutsiya testosteronzamestitel'noy terapii. Novye formy – novye vozmozhnosti. Endokrinologiya: novosti, mneniya, obuchenie. 2017;(2):55-65. (In Russ)]

The authors declare that there are no conflicts of interest present.